AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28715495 — intervention group
Group type: COMPARATOR
Intervention: Neutral control training
Number of subjects: 119
Study 28715495 — intervention group
Group type: EXPERIMENTAL
Intervention: All training paradigms
Number of subjects: 119
Study 26169803 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Medical Visits (GMVs)
Number of subjects: 128
Study 26169803 — intervention group
Group type: COMPARATOR
Intervention: Individual visits (Standard Care)
Number of subjects: 128
Study 23531280 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (as sodium selenite) per os on the days of RT
Number of subjects: 81
Study 21920001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 5μg once daily
Number of subjects: 343
Study 21920001 — intervention group
Group type: COMPARATOR
Intervention: Mebeverine 135 mg three times daily
Number of subjects: 343
Study 19369404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) - target dosage 3 g/d
Number of subjects: 370
Study 19369404 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC) - 0.5 to 1.0 g/m(2) in monthly pulses
Number of subjects: 370
Study 19369404 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d
Number of subjects: 370
Study 19369404 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endpoint
Number of subjects: 370
Study 19369404 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints
Number of subjects: 370
Study 19369404 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaths
Number of subjects: 370
Study 16673804 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray
Number of subjects: 27
Study 16673804 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 27
Study 15522039 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic administration of acetylcholine (ACh)
Number of subjects: 39
Study 15522039 — intervention group
Group type: COMPARATOR
Intervention: Postocclusive reactive hyperaemia
Number of subjects: 39
Study 15522039 — intervention group
Group type: COMPARATOR
Intervention: Brachial artery flow-mediated dilatation (FMD)
Number of subjects: 39
Study 11284539 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing sugar-free gum (one piece chewed for 30 min 4 times per day)
Number of subjects: 11
Study 11284539 — intervention group
Group type: COMPARATOR
Intervention: No gum chewing
Number of subjects: 11
Study 9337490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression (CBT-D)
Number of subjects: 35
Study 9337490 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training control (RTC)
Number of subjects: 35
Study 8324641 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 83
Study 3526151 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg every six hours)
Number of subjects: 576
Study 3526151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 29185022 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine ER (daily dose range 50 to 800 mg)
Number of subjects: 113
Study 29185022 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole (daily dose range 2.5 to 30 mg)
Number of subjects: 113
Study 27294404 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated blood eosinophils at 4 weeks of life (≥ 5% of total leukocytes)
Number of subjects: 559
Study 27294404 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophil counts at 7 months of life (≥ 5%)
Number of subjects: 559
Study 27294404 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophils at 4.5% at 7 months of life
Number of subjects: 559
Study 24072337 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day rosuvastatin
Number of subjects: 0
Study 24072337 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 0
Study 20970202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 64
Study 20970202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20829157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with 0.02 taper gutta‐percha cones and AH 26 sealer cement
Number of subjects: 3
Study 20829157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with 0.02 taper Resilon cones and Epiphany sealer
Number of subjects: 3
Study 20829157 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cone technique with 0.04 taper Resilon cones and Epiphany sealer
Number of subjects: 3
Study 19055278 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-medicine group (scalp electroacupuncture + Nimodipine)
Number of subjects: 270
Study 19055278 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group (scalp electroacupuncture)
Number of subjects: 270
Study 19055278 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Nimodipine only)
Number of subjects: 270
Study 19055278 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-medicine group and Electroacupuncture group
Number of subjects: 270
Study 16091876 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammalinolenic acid (GLA) levels in eczema patients with elevated IgE (Group A, n = 15)
Number of subjects: 22
Study 16091876 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammalinolenic acid (GLA) levels in atopic controls (Group C, n = 8)
Number of subjects: 22
Study 16091876 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammalinolenic acid (GLA) levels in eczema patients with normal IgE (Group B, n = 7)
Number of subjects: 22
Study 16091876 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammalinolenic acid (GLA) levels in non-atopic controls (Group D, n = 6)
Number of subjects: 22
Study 16091876 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of total IgE levels with GLA
Number of subjects: 22
Study 16091876 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of total IgE levels with arachidonic acid (AA)
Number of subjects: 22
Study 16091876 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression line slope for low-IgE responders (Groups B and D)
Number of subjects: 22
Study 16091876 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression line slope for high-IgE responders (Groups A and C)
Number of subjects: 22
Study 12054324 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Supportive-Expressive Group Psychotherapy
Number of subjects: 133
Study 12054324 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 133
Study 9929747 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7583550 — intervention group
Group type: EXPERIMENTAL
Intervention: Major locus with a codominant mixture model including sex, age, plasma concentrations of apoAI and triglycerides, exogenous sex hormone use, and menopausal status.
Number of subjects: 526
Study 7583550 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of four covariates (sex, age, apoAI, triglycerides) in the model.
Number of subjects: 526
Study 7583550 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage analyses with penetrance parameter estimates from segregation analysis.
Number of subjects: 526
Study 2285001 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (oral formulation)
Number of subjects: 100
Study 2285001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7015820 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplements
Number of subjects: 94
Study 7015820 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 94
Study 29955161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (48IU/day, n=53)
Number of subjects: 106
Study 29955161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=53)
Number of subjects: 106
Study 29609133 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention on substance use
Number of subjects: 151
Study 29609133 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 151
Study 29609133 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier smokers
Number of subjects: 151
Study 29609133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to quit smoking
Number of subjects: 151
Study 27102196 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health interventions including training of community health workers and traditional birth attendants, establishment of community health clubs, and mobile clinic services.
Number of subjects: 13423
Study 27102196 — intervention group
Group type: COMPARATOR
Intervention: Usual services provided to the control group.
Number of subjects: 13423
Study 25399620 — intervention group
Group type: EXPERIMENTAL
Intervention: Fillerina®
Number of subjects: 40
Study 21914717 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 45
Study 21914717 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluorescent blue light
Number of subjects: 45
Study 21914717 — intervention group
Group type: COMPARATOR
Intervention: Conventional halogen light
Number of subjects: 45
Study 20299958 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 126
Study 20299958 — intervention group
Group type: COMPARATOR
Intervention: Control clusters (minimal IPT use)
Number of subjects: 126
Study 20299958 — intervention group
Group type: COMPARATOR
Intervention: Laboratory substudy
Number of subjects: 126
Study 18612574 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) for alcohol-related problems (n = 562)
Number of subjects: 1684
Study 18612574 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) for physical/sexual abuse and sexual orientation (n = 563)
Number of subjects: 1684
Study 18612574 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) for respondents aged 18-39 (n = 563)
Number of subjects: 1684
Study 18612574 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 559)
Number of subjects: 1684
Study 16076741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontology display with history representation
Number of subjects: 30
Study 16076741 — intervention group
Group type: EXPERIMENTAL
Intervention: Compatibility between types of ontology display and history representation
Number of subjects: 30
Study 12397049 — intervention group
Group type: COMPARATOR
Intervention: Systolic Blood Pressure (BP)
Number of subjects: 2181
Study 12397049 — intervention group
Group type: COMPARATOR
Intervention: Diastolic Blood Pressure (BP)
Number of subjects: 2181
Study 12397049 — intervention group
Group type: COMPARATOR
Intervention: Pulse Pressure
Number of subjects: 2181
Study 12397049 — intervention group
Group type: COMPARATOR
Intervention: Mean Arterial Pressure
Number of subjects: 2181
Study 10572081 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (2.5 microg/kg/d or 5 microg/kg/d for up to 21 doses)
Number of subjects: 108
Study 10572081 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (2.5 microg/kg, single dose) and 7 daily doses of 2.5 microg/kg
Number of subjects: 108
Study 10572081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 10572081 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (group A)
Number of subjects: 108
Study 10572081 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (group B)
Number of subjects: 108
Study 10572081 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 108
Study 10572081 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF
Number of subjects: 108
Study 8649492 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 576
Study 8649492 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 576
Study 1804861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Number of subjects: 20
Study 6558295 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care instruction program adapted from the Health PACT program
Number of subjects: 42
Study 6558295 — intervention group
Group type: COMPARATOR
Intervention: Health discussion (Control group)
Number of subjects: 42
Study 30191779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mamma Mia (internet-based intervention)
Number of subjects: 1342
Study 30191779 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1342
Study 30403270 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions including four educational sessions on strategies for lowering blood sugar, increasing physical activity, promoting weight loss, prudent diet, and foot caring, followed for 12 weeks.
Number of subjects: 74
Study 30403270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 74
Study 26959810 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment group
Number of subjects: 75
Study 26959810 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-treatment mTBI group
Number of subjects: 75
Study 26959810 — intervention group
Group type: COMPARATOR
Intervention: Control group (orthopedic injury)
Number of subjects: 75
Study 24909836 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal psychoeducation programme
Number of subjects: 114
Study 24909836 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 114
Study 22300780 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (30 seconds interval, passive recovery)
Number of subjects: 20
Study 22300780 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (30 seconds interval, active recovery)
Number of subjects: 20
Study 22300780 — intervention group
Group type: COMPARATOR
Intervention: Protocol C (90 seconds interval, passive recovery)
Number of subjects: 20
Study 22300780 — intervention group
Group type: COMPARATOR
Intervention: Protocol D (90 seconds interval, active recovery)
Number of subjects: 20
Study 20334688 — intervention group
Group type: EXPERIMENTAL
Intervention: OAKP (Osteoarthritis Knee Program)
Number of subjects: 146
Study 20334688 — intervention group
Group type: COMPARATOR
Intervention: ASMP (Arthritis Self-Management Program)
Number of subjects: 146
Study 20334688 — intervention group
Group type: EXPERIMENTAL
Intervention: OAKP and ASMP
Number of subjects: 146
Study 18560642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined composite-amalgam restoration (ADAC, ADACM)
Number of subjects: 48
Study 18560642 — intervention group
Group type: COMPARATOR
Intervention: All amalgam restoration (AM)
Number of subjects: 48
Study 18560642 — intervention group
Group type: COMPARATOR
Intervention: All amalgam plus dentin adhesive (ADA)
Number of subjects: 48
Study 18560642 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam plus dentin adhesive plus composite resin (ADAC)
Number of subjects: 48
Study 18560642 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam plus dentin adhesive plus composite resin with modified preparation design (ADACM)
Number of subjects: 48
Study 15866966 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed manual instruction
Number of subjects: 93
Study 15866966 — intervention group
Group type: EXPERIMENTAL
Intervention: Video instruction
Number of subjects: 93
Study 15866966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on instruction
Number of subjects: 93
Study 15866966 — intervention group
Group type: COMPARATOR
Intervention: All training groups
Number of subjects: 93
Study 15866966 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after instruction
Number of subjects: 93
Study 15866966 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups before instruction
Number of subjects: 93
Study 12456943 — intervention group
Group type: COMPARATOR
Intervention: Control children (133 patients)
Number of subjects: 164
Study 12456943 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with CHF (31 patients)
Number of subjects: 164
Study 10325274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 187
Study 10325274 — intervention group
Group type: COMPARATOR
Intervention: Clinical touch embryo transfer
Number of subjects: 187
Study 10325274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer in older women (>=37 years old)
Number of subjects: 187
Study 10325274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer in difficult procedures
Number of subjects: 187
Study 10325274 — intervention group
Group type: COMPARATOR
Intervention: Clinical touch embryo transfer in difficult procedures
Number of subjects: 187
Study 8960901 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP 0.26 microgram/kg body weight i.v.
Number of subjects: 9
Study 8960901 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study 2015147 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine alone
Number of subjects: 4
Study 2015147 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine with adrenaline
Number of subjects: 4
Study 2015147 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine with fentanyl
Number of subjects: 4
Study 2015147 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine with adrenaline and fentanyl
Number of subjects: 4
Study 6613714 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention in Experiment 1 (n = 24)
Number of subjects: 64
Study 6613714 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention in Experiment 2 (n = 40)
Number of subjects: 64
Study 30822290 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance and resistance training exercise (ERTE)
Number of subjects: 25
Study 30822290 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 27044968 — intervention group
Group type: EXPERIMENTAL
Intervention: Summarized cost information
Number of subjects: 1025
Study 27044968 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality stars displayed adjacent to cost information
Number of subjects: 1025
Study 27044968 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of quality stars
Number of subjects: 1025
Study 27044968 — intervention group
Group type: EXPERIMENTAL
Intervention: Highlighting high-value plans with a check mark or blue ribbon
Number of subjects: 1025
Study 24703685 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) for both femur and tibia
Number of subjects: 107
Study 24703685 — intervention group
Group type: COMPARATOR
Intervention: Extramedullary guide for tibia and intramedullary guide for femur
Number of subjects: 107
Study 24703685 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary guides for both femur and tibia
Number of subjects: 107
Study 24703685 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical axis within ±3° of neutral
Number of subjects: 107
Study 24703685 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical axis outside ±3° of neutral
Number of subjects: 107
Study 22365936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored newsletter
Number of subjects: 225
Study 22365936 — intervention group
Group type: COMPARATOR
Intervention: Standard newsletter
Number of subjects: 225
Study 20031608 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR treatment
Number of subjects: 0
Study 20031608 — intervention group
Group type: COMPARATOR
Intervention: Atenolol treatment
Number of subjects: 0
Study 20031608 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil treatment
Number of subjects: 0
Study 17257175 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 30 mg i.v.
Number of subjects: 179
Study 17257175 — intervention group
Group type: COMPARATOR
Intervention: dexamethasone 4 mg i.v.
Number of subjects: 179
Study 17257175 — intervention group
Group type: COMPARATOR
Intervention: betamethasone 12 mg i.m.
Number of subjects: 179
Study 18080351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% PRO 2000
Number of subjects: 360
Study 18080351 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo gel
Number of subjects: 360
Study 18080351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% PRO 2000 or matched placebo gel
Number of subjects: 360
Study 15016290 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation-only A trials followed by B location search
Number of subjects: 0
Study 11269542 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 279
Study 9382514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of 5-FU, epirubicin and MMC (FEM group: n=7)
Number of subjects: 17
Study 9382514 — intervention group
Group type: COMPARATOR
Intervention: Other antineoplastic agents (non-FEM group: n=10)
Number of subjects: 17
Study 8439641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.d.)
Number of subjects: 251
Study 8439641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 2875907 — intervention group
Group type: EXPERIMENTAL
Intervention: Temelastine 50 mg
Number of subjects: 12
Study 2875907 — intervention group
Group type: EXPERIMENTAL
Intervention: Temelastine 100 mg
Number of subjects: 12
Study 2875907 — intervention group
Group type: EXPERIMENTAL
Intervention: Temelastine 200 mg
Number of subjects: 12
Study 2875907 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine 4 mg (Control)
Number of subjects: 12
Study 31025804 — intervention group
Group type: EXPERIMENTAL
Intervention: UT-DSAEK
Number of subjects: 64
Study 31025804 — intervention group
Group type: COMPARATOR
Intervention: DSAEK
Number of subjects: 64
Study 28750067 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular county council workshop training followed by six sessions of supervision
Number of subjects: 174
Study 28750067 — intervention group
Group type: COMPARATOR
Intervention: Regular county council workshop training
Number of subjects: 174
Study 28750067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (workshop training and supervision)
Number of subjects: 174
Study 25851642 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation-based training
Number of subjects: 31